Is tirzepatide a GLP-1?

Tirzepatide activates the GLP-1 receptor and also the GIP receptor, so it is often grouped with GLP-1 medications but is more precisely described as a dual GIP/GLP-1 receptor agonist.

Can I buy semaglutide or tirzepatide as a generic?

No. There are no FDA-approved generics for either ingredient. Products advertised as generic or compounded versions are not FDA-approved drugs — see our guide to compounded GLP-1 medications.

Comparison

Semaglutide vs. Tirzepatide: Side-by-Side Comparison

Semaglutide and tirzepatide are the two active ingredients behind most of today’s prescription weight-management injections. Semaglutide acts on one hormone receptor (GLP-1); tirzepatide acts on two (GIP and GLP-1). Each is sold under separate brand names approved for different indications.

Editorially reviewed by the editorial teamLast updated August 12, 2026

Side-by-side comparison

Semaglutide vs. Tirzepatide
	Semaglutide	Tirzepatide
Active ingredient	Semaglutide	Tirzepatide
Drug class	GLP-1 receptor agonist	Dual GIP and GLP-1 receptor agonist
Manufacturer	Novo Nordisk	Eli Lilly and Company
FDA status (for weight management)	FDA ApprovedApproved for chronic weight management	FDA ApprovedApproved for chronic weight management
Approved indications	Chronic weight management (as Wegovy) in adults and pediatric patients aged 12 and older, as an adjunct to a reduced-calorie diet and increased physical activity Reduction of major adverse cardiovascular event risk (as Wegovy) in adults with established cardiovascular disease and either obesity or overweight Type 2 diabetes (as Ozempic, injectable; and Rybelsus, oral) — a different indication from weight management	Chronic weight management (as Zepbound) in adults with obesity, or overweight with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity Moderate-to-severe obstructive sleep apnea in adults with obesity (as Zepbound) Type 2 diabetes (as Mounjaro) — a different indication from weight management
Administration	Subcutaneous injection (Wegovy, Ozempic) or oral tablet (Rybelsus)	Subcutaneous injection
Frequency	Once weekly (injectable); once daily (oral)	Once weekly
Approval date	First semaglutide approval: December 2017 (Ozempic). Weight-management approval: June 2021 (Wegovy).	First tirzepatide approval: May 2022 (Mounjaro). Weight-management approval: November 2023 (Zepbound).
Boxed warning	Yes — see drug page	Yes — see drug page
Common adverse reactions (from labeling)	Nausea, Diarrhea, Vomiting, Constipation, Abdominal pain, Headache, Fatigue, Dyspepsia (indigestion), Dizziness	Nausea, Diarrhea, Vomiting, Constipation, Abdominal pain, Dyspepsia (indigestion), Injection site reactions, Fatigue
Official information source	Prescribing information	Prescribing information

Every cell is drawn from the two medications’ FDA labeling as recorded on their individual pages: Semaglutide and Tirzepatide. Where labeling does not establish a fact, the cell says so.

Key differences

Mechanism: semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 receptor agonist.
Manufacturer: semaglutide is made by Novo Nordisk; tirzepatide by Eli Lilly.
Brands for weight management: semaglutide → Wegovy; tirzepatide → Zepbound.
Brands for type 2 diabetes: semaglutide → Ozempic (injection) and Rybelsus (oral tablet); tirzepatide → Mounjaro.
Semaglutide has an FDA-approved oral form (Rybelsus, for type 2 diabetes); tirzepatide is injection-only.
Neither ingredient has an FDA-approved generic. Compounded versions are not FDA approved.

Important safety differences

Both classes of product carry the same boxed warning regarding thyroid C-cell tumors in rodents, and the same MTC/MEN 2 contraindications.
Most common adverse reactions in the labeling for both are gastrointestinal.
Which is better tolerated by a given person cannot be predicted from labeling alone — that is a clinical discussion.

Read both full labels

Summaries cannot substitute for the prescribing information. Both labels are linked in the table above and in Sources below.

Which one is right for you?

We can’t answer that, and neither can any website. Choosing between weight-management medications depends on your medical history, other conditions and medications, what your insurance covers, and how you tolerate a given drug — all of which require a licensed clinician who knows your case. What we can do is make sure the facts you bring to that conversation are accurate and traceable to their source.

Frequently asked questions

Is tirzepatide a GLP-1?: Tirzepatide activates the GLP-1 receptor and also the GIP receptor, so it is often grouped with GLP-1 medications but is more precisely described as a dual GIP/GLP-1 receptor agonist.
Can I buy semaglutide or tirzepatide as a generic?: No. There are no FDA-approved generics for either ingredient. Products advertised as generic or compounded versions are not FDA-approved drugs — see our guide to compounded GLP-1 medications.

Sources

Semaglutide prescribing information (DailyMed, NIH) — DailyMed/NIH. Link last verified August 12, 2026.
FDA: Medications containing semaglutide — FDA. Link last verified August 12, 2026.
Drugs@FDA database — FDA. Link last verified August 12, 2026.
Tirzepatide prescribing information (DailyMed, NIH) — DailyMed/NIH. Link last verified August 12, 2026.
FDA: concerns with unapproved GLP-1 drugs — FDA. Link last verified August 12, 2026.

Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.